|
|
Vaccine Detail
|
ALVAC-CEA B7.1 Vaccine |
| Vaccine Information |
- Vaccine Name: ALVAC-CEA B7.1 Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007243
- Type: Recombinant vector vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- Antigen: CEA
- CD80
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- Preparation: ALVAC-CEA/B7.1 was prepared by recombinant engineering. On the day of vaccination, the vaccine was reconstituted with 1 mL of 0.4% NaCl diluent and shaken gently. A sterile syringe was used to inject 1 mL of solution s.c. in the deltoid region (Kaufman et al., 2008).
- Description: A cancer vaccine that uses a viral vector system derived from the canarypox virus engineered to target the carcinoembryonic antigen (CEA). It causes infected cells to temporarily display CEA and activates the immune system to attack the tumor cells. (NCIT_C1977). This vaccine has been used in metastatic colon cancer patients. (Kaufman et al., 2008)
|
| Host Response |
|
|
| References |
Kaufman et al., 2008: Kaufman HL, Lenz HJ, Marshall J, Singh D, Garett C, Cripps C, Moore M, von Mehren M, Dalfen R, Heim WJ, Conry RM, Urba WJ, Benson AB 3rd, Yu M, Caterini J, Kim-Schulze S, Debenedette M, Salha D, Vogel T, Elias I, Berinstein NL. Combination chemotherapy and ALVAC-CEA/B7.1 vaccine in patients with metastatic colorectal cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2008; 14(15); 4843-4849. [PubMed: 18676757].
NCIT_C1977: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1977]
|
|
